PROMININ-1 (CD133) AS THERAPEUTIC CANCER TARGET

PROMININ-1 (CD133) 作为癌症治疗靶点

• 批准号: 8360615
• 负责人: AURELIO LORICO
• 金额: $ 7.67万
• 依托单位: UNIVERSITY OF NEVADA RENO
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360615
• 关键词: Biomedical Research; Cell Fraction; Cell Surface Extensions; Clinical; Data; Eye; Funding; Grant; Human; Immunotoxins; Laboratories; Location; Malignant Neoplasms; Melanoma Cell; Membrane Glycoproteins; Molecular Target; Morphogenesis; Names; National Center for Research Resources; Neoplasm Metastasis; Pathway interactions; Pharmaceutical Preparations; Physiological; Population; Principal Investigator; Proteins; Reporting; Research; Research Infrastructure; Resources; Signal Pathway; Signaling Pathway Gene; Source; Stomach; Systemic Therapy; Therapeutic; Therapeutic Intervention; United States National Institutes of Health; cancer stem cell; cancer type; cell growth; cell motility; cellular targeting; cost; in vivo; malignant phenotype; photoreceptor disc; prominin; tumor; tumor progression; yeast two hybrid system

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The identification of the sub-population of cancer stem cells (CSC), responsible for cancer progression and metastasis (cellular target) and the discovery of proteins or pathways relevant to the malignant phenotype (molecular target), are very important to tailor appropriate systemic therapies. Prominin-1 (CD133), a cell-surface glycoprotein, named for its prominent location on the protrusion of cell membranes, has the potential to identify the cellular target and to constitute a molecular target for some types of cancer. CD133 has now been recognized as the most important CSC-associated marker identified so far, with increased expression in the CSC fraction of a large variety of human malignancies. The physiological function(s) of CD133 are unknown, except in the eye, where it is involved in photoreceptor disk morphogenesis. We have previously found that CD133 knockdown slowed cell growth, decreased cell motility, and reduced the capacity of human melanoma cells to metastasize. These data, together with the recent report of in vivo antitumor efficacy of an anti-CD133-drug conjugate in hepatocellular and gastric cancers11, strongly suggest that (i) CD133 is an important potential target per se, and (ii) targeting CD133 has potential clinical utility against CD133-expressing tumors. We are currently pursuing the following aims in our laboratory: A. Discovery of CD133 protein interactors by the yeast "two-hybrid" system. B. Discovery of additional (non-physical) interactions of CD133 with cellular genes and signaling pathways. C. To investigate the potential of anti-CD133 immunotoxins and of newly discovered CD133-interacting proteins or CD133-associated signaling pathways as targets for cancer therapeutic intervention.

这个子项目是利用这些资源的众多研究子项目之一